“We have seen firsthand the value such tools can create for life science organizations. With the release of this new paper, we’re hoping to highlight that value as well as some of the concerns that come with tool adoption and implementation.”

LEXINGTON, Mass. (PRWEB)
November 26, 2019

Cognition Corporation, a software company specializing in medical device compliance and commercialization, has just released a new eBook on adopting compliance software tools in life science product development.

Compliance software tools are often leveraged by life science organizations to manage the complexities of compliance with regulatory requirements and international standards. These electronic systems offer development teams distinct advantages in both the premarket and postmarket management of their products.

“As a vendor of a compliance software ourselves,” says David Cronin, CEO of Cognition Corporation, “We have seen firsthand the value such tools can create for life science organizations. With the release of this new paper, we’re hoping to highlight that value as well as some of the concerns that come with tool adoption and implementation.”

The new white paper outlines some of the key benefits compliance software adoption can bring to life science organizations, including the streamlining of necessary compliance activities and greater levels of accountability. It further goes on to explore some of the key challenges that companies need to consider before they move forward with adoption.

“As with any other part of the total product life cycle and quality management system for life sciences, there’s a certain amount of risk involved with implementing new software,” says Mr. Cronin. “Rather than just extolling the benefits of a compliance platform for life science businesses, we wanted to use this white paper as an opportunity to explore the fuller picture.”

Mr. Cronin adds that he hopes using this white paper to provide a clearer frame into the world of compliance software adoption, businesses looking to make a transition to newer tools are armed with the most information possible. “We understand how critical the decision to take on any new tool can be in product development, and we hope we can leverage our experience and share what we know with those who need it.”

The eBook is available for download here.

Cognition Corporation, based in Lexington, Massachusetts, has offered solutions for product development compliance for more than fifteen years. Cognition offers the Cognition Cockpit® Platform, along with engineering and validation support, and industry expertise. Thousands of users worldwide use Cognition solutions to manage their product development process and meet regulatory, performance, and-time to-market goals. For more information, visit http://www.cognition.us or call (781) 271-9300.

Share article on social media or email:

We are thrilled to offer the opportunity for our colleagues to learn directly from Dr. Als

CINCINNATI (PRWEB)
November 25, 2019

The National Association of Neonatal Therapists (NANT) will host a live, 120-minute Virtual Summit with live Q & A on Wednesday, December 4th from 1:00 – 3:00 PM EST in webinar format.

The special guest presenter will be none other than the esteemed Dr. Heidelise Als from Harvard Medical School and Boston Children’s Hospital. This presentation will inform participants of the importance of reading the newborn infant’s behavioral language astutely. Participants will also learn about the ways that care and the environment support and protect or challenge and threaten the immature infant’s brain development. The importance of the parents in nurturing and regulation of their infants at all times will be highlighted.

“This content, presented by the originator of the program, must be well understood and integrated by all neonatal professionals in order to collaboratively provide the best care possible for infants in the neonatal intensive care unit,” states NANT Founder and President Sue Ludwig, OTR/L, CNT. “We are thrilled to offer the opportunity for our colleagues to learn directly from Dr. Als.”

The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) – Promise to Protect the Preterm Brain is a complimentary virtual event. It will include a Q & A session at the conclusion of the program, and a recording will be made available to all registrants.

This course offers CE Credit for OTs, PTs, SLPs and Nurses. Learners must attend and complete the entire presentation. Participants who complete the recorded presentation must also complete a learning assessment in order to receive CE Credit. No partial credit will be awarded.

“The structure of this annual online event is ideal for introducing highly relevant subject matter to a global audience,” said Ludwig.

Attendees must register for The NANT Virtual Summit in order to attend the 120-minute webinar. Visit http://nantvirtualsummit.com to register and for more information. This is time sensitive, as the Summit takes place on Wednesday, December 4th.

The National Association of Neonatal Therapists (NANT) is an organization created specifically for neonatal occupational therapists, physical therapists, and speech-language pathologists. NANT provides multiple ways for neonatal therapists to connect, learn, mentor, and inspire while advancing this focused field of therapy on a global level.

Questions regarding CE credit should be directed to the National Association of Neonatal Therapists at info@neonataltherapists.com or (866) 999-5524.

Share article on social media or email:

“It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy,” Herzog says.

MILWAUKEE (PRWEB)
November 25, 2019

The American Society of Gene & Cell Therapy (ASGCT) announced today the appointment of Roland W. Herzog, Ph.D. and Gerhard Bauer as editors-in-chief of the Society’s field-leading journals, Molecular Therapy and Molecular Therapy—Methods & Clinical Development, respectively. Both editors will begin their positions effective January 1, 2020.

Herzog, currently the editor-in-chief of Molecular Therapy—Methods & Clinical Development, will assume the same role for a five-year term at Molecular Therapy from Seppo Ylä-Herttuala, M.D., Ph.D. at the conclusion of Ylä-Herttuala’s term. Herzog is also a professor of pediatrics, Riley Children’s Foundation Professor of Immunology, and director of the gene and cell therapy program at Indiana University.

“It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy,” Herzog says. “My vision has continued and even further strengthened close coordination and collaboration between the journal editors and partnership with Cell Press and ASGCT.”

Bauer replaces Herzog at the helm of Molecular Therapy—Methods & Clinical Development after serving as an associate editor of the same journal for more than four years. Bauer is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures.

“Over the years that I have been looking at manuscripts submitted to the journal, I have always loved the articles dealing with translational research, getting the products ready for clinical applications, improving their utility and solving problems in the manufacturing of these products,” Bauer says. “Now, at a time where we have clinical efficacy and also commercially approved cell and gene therapy products that save lives, it is even more important to strengthen the translational research field.”

ASGCT’s official journal, Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy’s 2018 impact factor is 8.402.

The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular Therapy—Methods & Clinical Development’s 2018 impact factor is 4.875.

In addition to Molecular Therapy and Molecular Therapy Methods & Clinical Development, ASGCT also owns and operates two other sibling journals, Molecular Therapy—Nucleic Acids (2018 impact factor 5.919) and Molecular Therapy—Oncolytics (2018 impact factor 5.710).

About ASGCT

The American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Share article on social media or email: